Bio-Rad Acquires Celsee, Inc., a Single-Cell Analysis Solutions Provider
09 April 2020 - 10:30PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced that it has acquired Celsee, Inc., a company that offers
instruments and consumables for the isolation, detection, and
analysis of single cells. Terms of the acquisition were not
disclosed. Bio-Rad will discuss the acquisition in more detail
during its first-quarter 2020 financial results conference
call.
Celsee’s Genesis System offers a practical, scalable, and
efficient approach to accurately analyze single cells. Using the
Genesis System, scientists can isolate, analyze, and interpret
cellular behavior and collect cell-based information for improved
results in applications such as single-cell cytometry, single-cell
transcriptomics, single-cell multiomics, rare-cell enrichment and
enumeration, and immune monitoring. The system can scale from
hundreds of thousands to millions of cells for genomic and
proteomic applications and can enrich or monitor circulating tumor
cells to determine disease progression and therapeutic
response.
“We are pleased to have Celsee join Bio-Rad,” said Norman
Schwartz, Bio-Rad President and CEO. “Their innovative products and
technologies will extend our reach into the rapidly growing world
of precision medicine and single-cell analysis, both of which offer
enhanced insight into disease, diagnosis, and treatment.”
Founded in 2011 and based in Ann Arbor, Michigan, Celsee’s
customers include research, translational, and biopharma
laboratories worldwide.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops,
manufactures, and markets a broad range of innovative products and
solutions for the life science research and clinical diagnostic
markets. The company is renowned for its commitment to quality and
customer service among university and research institutions,
hospitals, public health and commercial laboratories, as well as
the biotechnology, pharmaceutical, and food safety industries.
Founded in 1952, Bio-Rad is based in Hercules, California, and
serves more than 150,000 research and healthcare industry customers
through its global network of operations. The company employs more
than 8,000 people worldwide and had revenues exceeding $2.3 billion
in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our expectations
regarding the acquisition of Celsee, Inc. Forward-looking
statements generally can be identified by the use of
forward-looking terminology such as, “believe,” “expect,”
“anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or
similar expressions or the negative of those terms or expressions,
although not all forward-looking statements contain these words.
Such statements involve risks and uncertainties, which could cause
actual results to vary materially from those expressed in or
indicated by the forward-looking statements. For further
information regarding the Company’s risks and uncertainties, please
refer to the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operation” in
Bio-Rad’s public reports filed with the Securities and Exchange
Commission, including our most recent Annual Report on Form 10-K
and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to
place undue reliance on forward-looking statements, which reflect
an analysis only and speak only as of the date hereof. We disclaim
any obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200409005252/en/
Bio-Rad Laboratories, Inc. Tina Cuccia, Corporate Communications
510-724-7000 tina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2024 to May 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From May 2023 to May 2024